Rxo (RXO) Revenue (2021 - 2026)

Rxo (RXO) has 6 years of Revenue data on file, last reported at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 0.56% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $5.7 billion (up 13.1% YoY), and the FY2025 full-year result was $5.7 billion, up 26.2% from the prior year.
• Revenue for Q1 2026 stood at $1.4 billion, down from $1.5 billion in the prior quarter.
• Across five years, Revenue topped out at $1.7 billion in Q4 2024 and bottomed at $913.0 million in Q1 2024.
• The 5-year median for Revenue is $1.1 billion (2022), against an average of $1.2 billion.
• The widest annual swing landed in 2023, when Revenue fell 23.02%; it then jumped 70.45% in 2024.
• A 5-year view of Revenue shows it stood at $1.1 billion in 2022, then decreased by 12.68% to $978.0 million in 2023, then surged by 70.45% to $1.7 billion in 2024, then fell by 11.88% to $1.5 billion in 2025, then decreased by 3.0% to $1.4 billion in 2026.
• The last three Revenue figures came in at $1.4 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.

Peer Comparison